2Mckeage k, Goakl. Lusulin glargine; ereven of its therapeutic use as along -actinh agent for management of trpe 1 ang 2 diabetes mellitus. Druge 2001 ; 61 : 1599 -624.
1Riddle MC,Rosenstock J,Gerich J.Insulin Glargine 4002 Study Investigators.The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care,2003; 26(11):3 080-3 086.
2HOE 901/3002 Study Group.Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes[J].Diabetes Care,2000; 23(8):1 130-1 136
3UKPDS Study Group.Stratton IM,Adler AI,Neil HAW,Matthews DR,Manley SE,Cull CA,Hadden D,Turner RC,Holman RR.Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes:prospective observational study (UKPDS 35) [J].BMJ,20
4Wright A,Burden ACF,Paisey RB.Sulfonylurea Inadequacy:Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)[J].Diabetes Care,2002; 25(2):330-336
5Turner RC,Cull CA,Frighi V,Holman RR.Glycemic control with diet,sulfonylurea,metformin,or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies (UKPDS 49).UK Prospective Diabetes Study (UKPDS) Group[J].JAMA,1999;
6UKPDS Study Group.Klein R,Klein BE,Moss SE.Relation of glycemic control to diabetic microvascular complications indiabetes mellitus[J].Ann Intern Med,1996;124(1 Pt 2):90-96
7UKPDS Study Group.Overview of six years' therapy of type 2 diabetes-a progressive disease (UKPDS 16)[J].Diabetes Care,1995; 44(11):1 249-1 258
